March 2023 Top Biopharma Deal: OncoC4 – BioNTech for ONC-392 for Solid Tumors and NSCLC
March 2023 Top Biopharma Deal Upfront
OncoC4 co-development and commercialization deal with BioNTech for ONC-392
Highlighted Deal Financial Comps
Date Announced:
March 20, 2023
Total Deal Value:
$200M + Mst
Upfront Cash:
$200M
Upfront Equity:
n/a
Option Payments:
n/a
Total Milestones:
Undisclosed dev., reg., and sales milestones
Royalties:
Undisclosed tiered double-digit royalties
Cost & Profit Split:
50% development cost split
Deal Synopsis
The Asset:
OncoC4's ONC-392 anti-CTLA-4 monoclonal antibody candidate in Phase II as monotherapy or in combination with anti-PD1 in various solid tumor indications, including immunotherapy-resistant non-small cell lung cancer (NSCLC).
Deal Structure:
Development and Commercial License
Partnership Features:
Co-Development, Shared Cost
Deal Details:
- OncoC4 granted BioNTech exclusive, worldwide rights to co-develop and commercialize OncoC4’s ONC-392, an anti-CTLA-4 mAb as a monotherapy and in combination with anti-PD-(L)-1 antibodies for the treatment of solid tumors, including NSCLC.
- OncoC4 and BioNTech will equally share the development costs while OncoC4 will negotiate for the commercialization of therapies in certain territories.
- OncoC4 will receive $200M up front and is eligible for undisclosed development, regulatory, and commercial milestones, plus tiered double-digit royalties.
Last Month:
Congrats to OncoC4 and BioNTech for landing DealForma’s March 2023 Top Biopharma Deal. Last month’s Deal of the Month was Axsome and Pharmanovia deal for Sunosi. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...